Synonyms: N-acetyltryptamine; N-acetyltryptamine monohydrochloride; NVUGEQAEQJTCIX-UHFFFAOYSA-N; MFCD00209910; N-[2-(1H-Indol-3-yl)-ethyl]-acetamide; Acetamide, N-(2-(1H-indol-3-yl)ethyl)-; SMR000686036; SR-01000075685; Acetotryptamide; Acetamide, N-(2-indol-3-ylethyl)-; Tocris-0357; AC1L2EBK; N-Acetyltryptamine; Lopac-A-7342; N-Acetyltryptamine, powder; AC1Q1L6A; 3-(2-Acetamidoethyl)indole; Lopac0_000101; MLS001250169; MLS002153204; SCHEMBL468850; AC1Q5P72; ISUPSL100255; 1016-47-3; ACon1_000465; CTK8G1571; N-(2-indol-3-ylethyl)acetamide; DTXSID30144042; HMS2270O21; HMS3260E04; HMS3266I05; HMS3675G05; ZINC174849; KS-000017TN; N-(2-(1H-indol-3-yl)ethyl)acetamide; Tox21_500101; 0428AA; BDBM50282758; PDSP1_001815; PDSP2_001798; STL352108; AKOS000639631; CCG-204196; LP00101; MCULE-3484861085; N-[2-(1H-Indol-3-yl)ethyl]acetamide; NCGC00015088-01; NCGC00015088-02; NCGC00015088-03; NCGC00015088-04; NCGC00015088-05; NCGC00015088-06; NCGC00015088-07; NCGC00015088-08; NCGC00015088-09; NCGC00024552-01; Acetamide, N-[2-(1H-indol-3-yl)ethyl]-; NCGC00024552-02; NCGC00024552-03; NCGC00024552-04; NCGC00024552-05; NCGC00024552-06; NCGC00260786-01; AJ-17612; ZB009323; N-[2-(1H-Indol-3-yl)ethyl]acetamide #; B6274; 3-(2-N-Acetylaminoethyl)indole; EU-0033445; EU-0100101; ST50409166; A 7342; Acetamide, N-(2-indol-3-ylethyl)- (7CI,8CI); Acetotryptamide N-Acetyl-2-(indol-3-yl)ethylamine; Acetamide, N-[2-(1H-indol-3-yl)ethyl]- (9CI); J-000457; SR-01000075685-1; SR-01000075685-2; CHEMBL33171; SR-01000075685-4; BRD-K73700643-001-04-7; BRD-K73700643-001-10-4; NCGC00015088-09_C12H14N2O_N-[2-(1H-Indol-3-yl)ethyl]acetamide; 374572-55-1; 7AN; C12H14N2O; CID70547; AR-1K3534; C12-H14-N2-O; CHEBI:55515; ~{n}-[2-(1~{h}-Indol-3-Yl)ethyl]ethanamide; A2685; 19231-22-2;